KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.

James Larkin, Mototsugu Oya, Marcella Martignoni, Fiona Thistlethwaite, Paul Nathan, Moshe C Ornstein, Thomas Powles, Kathryn E Beckermann, Arjun V Balar, David McDermott, Sumati Gupta, George K Philips, Michael S Gordon, Hirotsugu Uemura, Yoshihiko Tomita, Jing Wang, Elisabete Michelon, Alessandra di Pietro, Toni K Choueiri

Oncologist 28(4) 333-340

PMID36576173
PMCIDPMC10078905
DOI10.1093/oncolo/oyac243
发表日期2022-12-28
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

BACKGROUND: Progression-free survival was significantly longer in patients who received avelumab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (aRCC) in a randomized phase III trial. We report long-term safety and efficacy of avelumab plus axitinib as first-line treatment for patients with aRCC from the JAVELIN Renal 100 phase Ib trial (NCT02493751). MATERIALS AND METHODS: In this open-label, multicenter, phase Ib study, patients with untreated aRCC received avelumab 10 mg/kg every 2 weeks plus axitinib 5 mg twice daily or with axitinib for 7 days followed by avelumab plus axitinib. Safety and efficacy were assessed in all patients receiving at least one dose of avelumab or axitinib. RESULTS: Overall, 55 patients were enrolled and treated. Median follow-up was 55.7 months (95% CI, 54.5-58.7). Treatment-related adverse events of any grade or grade ≥3 occurred in 54 (98.2%) and 34 (61.8%) patients, respectively. The confirmed objective response rate was 60.0% (95% CI, 45.9-73.0), including complete response in 10.9% of patients. Median duration of response was 35.9 months (95% CI, 12.7-52.9); the probability of response was 65.8% (95% CI, 46.7-79.4) at 2 years. Median progression-free survival was 8.3 months (95% CI, 5.3-32.0). Median overall survival was not reached (95% CI, 40.8-not estimable); the 5-year overall survival rate was 57.3% (95% CI, 41.2-70.5). CONCLUSION: Five-year follow-up for combination treatment with avelumab plus axitinib in previously untreated patients with aRCC showed long-term clinical activity with no new safety signals, supporting use of this regimen within its approved indication in clinical practice (Clinicaltrials.gov NCT02493751).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。